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ABSTRACT
A critical barrier in the treatment of endosomal and lysosomal
diseases is the lack of understanding of the in vivo functions of the
putative causative genes. We addressed this by investigating a key
pair of endocytic adaptor proteins, PH domain-containing endocytic
trafficking adaptor 1 and 2 (PHETA1/2; also known as FAM109A/B,
Ses1/2, IPIP27A/B), which interact with the protein product of OCRL,
the causative gene for Lowe syndrome. Here, we conducted the first
study of PHETA1/2 in vivo, utilizing the zebrafish system. We
found that impairment of both zebrafish orthologs, pheta1
and pheta2, disrupted endocytosis and ciliogenesis in renal tissues.
In addition, pheta1/2 mutant animals exhibited reduced jaw size and
delayed chondrocyte differentiation, indicating a role in craniofacial
development. Deficiency of pheta1/2 resulted in dysregulation of
cathepsin K, which led to an increased abundance of type II collagen
in craniofacial cartilages, a marker of immature cartilage extracellular
matrix. Cathepsin K inhibition rescued the craniofacial phenotypes in
the pheta1/2 double mutants. The abnormal renal and craniofacial
phenotypes in the pheta1/2 mutant animals were consistent with the
clinical presentation of a patient with a de novo arginine (R) to
cysteine (C) variant (R6C) of PHETA1. Expressing the patient-
specific variant in zebrafish exacerbated craniofacial deficits,
suggesting that the R6C allele acts in a dominant-negative manner.
Together, these results provide insights into the in vivo roles of
PHETA1/2 and suggest that the R6C variant is contributory to the
pathogenesis of disease in the patient.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Endocytic trafficking is essential for a variety of biological
processes, including nutrient uptake, cell signaling and cellular
morphogenesis (Doherty and McMahon, 2009). This diversity in
cellular functions is reflected in the broad range of pathologies
associated with deficiencies in endocytic factors. For example,
mutations in endocytic factors dynamin 2 (DNM2) and RAB7 result
in Charcot-Marie-Tooth disease, a clinically and genetically
heterogeneous group of peripheral neuropathies (Verhoeven et al.,
2003; Züchner et al., 2005). Disruptions in endocytosis have been
identified in autosomal recessive hypercholesterolemia (Garuti
et al., 2005) and autosomal dominant polycystic kidney disease
(Obermuller et al., 2001). These disparate clinical outcomes
resulting from endocytic protein deficiency underscore the
importance of investigations in the organismal context. Currently,
endocytic pathways have been identified and defined through their
differential interactions with specific phosphoinositides and
proteins (e.g. clathrin, actin and dynamin), but most components
of the endocytic machinery have only been examined in cell lines
(Doherty andMcMahon, 2009). In this study, our goal was to use an
in vivo experimental system to investigate two important regulators
of endocytosis, PH domain-containing endocytic trafficking
adaptor 1 and 2 (PHETA1/2).
PHETA1/2 (also known as FAM109A/B, Ses1/2, IPIP27A/B)
were identified in vitro as regulators of endosomal trafficking,
specifically for receptor recycling to endosomes and for cargo
sorting to lysosomes (Noakes et al., 2011; Swan et al., 2010). Both
PHETA1 and PHETA2 have a C-terminal phenylalanine-histidine
motif (F&H motif ) that serves as a binding site for OCRL, encoded
by a gene that is mutated in Lowe syndrome (MIM #309000)
(Pirruccello et al., 2011). OCRL is an inositol 5-phosphatase, with
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] as the preferred
substrate (Attree et al., 1992; Noakes et al., 2011). Binding to
PI(4,5)P2 occurs at the pleckstrin homology (PH) domain in OCRL,
which also contains a loop outside the domain fold with a clathrin-
binding motif. This motif directs OCRL specifically to clathrin-
coated endocytic pits on the plasma membrane (Choudhury et al.,
2009; Mao et al., 2009). PI(4,5)P2 is abundant at the plasmaReceived 8 August 2019; Accepted 27 February 2020
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membrane and is involved in a wide variety of processes, including
actin dynamics and endocytosis (Sasaki et al., 2009). Disrupting the
phosphatase activity of OCRL interferes with PI(4,5)P2 homeostasis,
which is thought to contribute to the disease manifestations of Lowe
syndrome (De Leo et al., 2016; Lowe, 2005; Vicinanza et al., 2011).
Several studies have shown that PHETA1 is crucial in maintaining
optimal OCRL function. Specifically, the 5-phosphatase activity of
OCRL relies upon PHETA1-mediated interaction with protein kinase
C and casein kinase substrate in neurons 2 (PACSIN2), a protein that
interacts with the actin cytoskeleton. A proline-rich PPPxPPRRmotif
in PHETA1 located upstream of the F&H motif serves as the
necessary PACSIN2 binding site (Billcliff et al., 2016). PHETA2
lacks the PPPxPPRRmotif. OCRL also promotes ciliogenesis byway
of endosomal trafficking in a Rab8 (also known as RAB8A)/
PHETA1-dependent manner (Coon et al., 2012). These findings
suggest that PHETA1 and OCRL functionally interact to mediate
both endocytosis and ciliogenesis.
Besides endocytosis and ciliogenesis, PHETA1 and PHETA2 are
also involved in the transport of newly synthesized lysosomal
hydrolases from the trans-Golgi network (TGN) to the endosomes
(Noakes et al., 2011). Thus, loss of PHETA1/2 could result in
improper sorting of lysosomal hydrolases. Consistent with this idea,
loss of PHETA2 results in hypersecretion of pro-cathepsin D
(Noakes et al., 2011). Similar disruptions in lysosomal proteins have
also been found in mucolipidosis type II (MLII), where the loss of
mannose 6-phosphate-dependent targeting results in hypersecretion
of multiple lysosomal enzymes (Kollmann et al., 2010; Kornfeld,
1986; Kudo et al., 2006). Dysregulation of cathepsins in MLII
zebrafish models results in craniofacial and skeletal deformations,
recapitulating the clinical features of MLII patients (Flanagan-Steet
et al., 2009; Petrey et al., 2012). Thus, PHETA1/2-dependent
regulation of protease transport may be important for craniofacial
development.
The involvement of PHETA1 during development is further
supported by recent findings in a human patient with a de novo
arginine to cysteine (R6C) variant in PHETA1, identified through
the National Institutes of Health (NIH) Undiagnosed Diseases
Program (UDP) (Gahl et al., 2012, 2016, 2015). The UDP patient
presented with global developmental delay, coarse facial features,
renal abnormalities and other developmental deficits (Table 1).
Despite the known roles of PHETA1 in facilitating OCRL function,
the UDP patient did not present with the typical manifestations of
Lowe syndrome, i.e. congenital cataracts, cognitive impairment, and
renal tubular and glomerular dysfunction (Mehta et al., 2014).
These findings suggest that PHETA1 may have OCRL-independent
functions in vivo.
To investigate the in vivo functions of PHETA1 and its close
homolog PHETA2, we utilize zebrafish, an informative small
vertebrate model organism for validating the pathogenicity of genes
or alleles in human patients. This approach has offered valuable
insight for clinicians into a broad range of genetic disorders,
including neurodevelopmental disorders, ciliopathies and Lowe
syndrome (Coon et al., 2012; Oltrabella et al., 2015; Phillips and
Westerfield, 2014; Ramirez et al., 2012; Sakai et al., 2018; Song
et al., 2016). Using histological, physiological and behavioral
analyses, we found that zebrafish pheta1 and pheta2 are required for
endocytosis, ciliogenesis and craniofacial development. Consistent
with a role in trafficking lysosomal enzymes, disruption in
craniofacial development in the pheta1/2 mutants was associated
with dysregulated cathepsin K activity. The abnormal craniofacial
development is exacerbated further in the presence of the R6C
variant, suggesting a dominant-negative mode of action in human
disease.
RESULTS
Identification of a de novo PHETA1 variant in undiagnosed
human disease
The UDP enrolled a 6-year-old female patient with craniofacial
dysmorphic features, scoliosis, clinodactyly, global developmental
delay, vision and auditory impairments, and renal tubular or
glomerular dysfunction (Fig. 1A,B and Table 1). Whole-exome
sequencing and Sanger sequencing of the patient, unaffected
fraternal twin and unaffected parents identified a heterozygous de
novo arginine (R) to cysteine (C) mutation in PHETA1, present only
in the patient (NM_001177997.2:c.55C>T; p.R6C in the short
isoform; p.R19C in the long isoform, NM_001177996.1) (Fig. 1C).
The R6 residue in PHETA1 is highly conserved across species
(Fig. 1D) (Papadopoulos and Agarwala, 2007), and the R6C
mutation was predicted to be damaging with the use of Polyphen
(Probably damaging, HumDiv: 1; HumVar: 0.995), SIFT
(Deleterious, Score 0.01), and MutationTaster (Disease causing,
Prob: 1) (Adzhubei et al., 2010; Schwarz et al., 2014; Sim et al.,
Table 1. Clinical features of a UDP patient affected with a de novo arginine (R) to cysteine (C) mutation in PHETA1
UDP_5532 patient clinical presentation
Presentation at
birth
Abnormality of the placenta, breech presentation (C-section performed), gestational diabetes, congenital bilateral hip dislocation,
congenital muscular torticollis, decreased body weight, birth length less than 3rd percentile, episodic vomiting, feeding difficulties in
infancy, self-injurious behavior, small for gestational age.
Facial features Facial asymmetry, coarse facial features, concave nasal ridge, flat occiput, malar flattening, narrow mouth, sparse scalp hair, relative
macrocephaly.
Brain Subdural hemorrhage, absence of acoustic reflex, ventriculomegaly, elevated brain lactate level by magnetic resonance spectroscopy
(MRS), reduced brain N-acetyl aspartate level by MRS, cavum septum pellucidum, widened subarachnoid space, decreased sensation
to painful stimuli.
Eyes Congenital exotropia, amblyopia, bilateral ptosis, hypertelorism, nystagmus, optic nerve dysplasia/hypoplasia, short palpebral fissure,
telecanthus. Patient had corrective surgery and vision is now normal.
Kidney Horseshoe kidney, oligosacchariduria.
Motor Broad-based gait, delayed fine and gross motor development, generalized hypotonia, oral motor hypotonia.
Hands/feet Clinodactyly of 4th and 5th finger, multiple palmar and plantar creases, pes planus, short foot and palm, tapered fingers, slow-growing
nails, metatarsus adductus.
Dental Abnormality of dental morphology, dental malocclusion, difficulty in tongue movements, widely spaced teeth.
Other Moderate receptive language delay, severe global developmental delay, hearing impairment, thoracolumbar kyphoscoliosis, chronic
constipation, mitral valve prolapse, freckled genitalia, hyperpigmented streaks, prominent crus of helix, upper airway obstruction, hip
dysplasia, seasonal allergy.
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2012). This variant has been reported in the ExAC browser, with a
minor allele frequency of 0.000009398 (1/106410). Using patient-
derived fibroblasts and quantitative real-time PCR (qRT-PCR), we
found that the R6C mutation does not affect the mRNA expression
of PHETA1 (Fig. 1E).
Protein modeling was performed using the I-TASSER,
MUSTER and PHYRE2 servers (Fig. 1F) (Adzhubei et al.,
2010; Kelley et al., 2015; Roy et al., 2010; Wu and Zhang, 2008).
Based on the homology model, the arginine residue (highlighted in
yellow) is far from the OCRL binding site (highlighted in
magenta). However, it stabilizes the folded domain around the
C-terminal helix, close to the F&H motif, such that the mutation is
predicted to disrupt the folded domain and thus may interfere with
OCRL binding to PHETA1. To test this, we expressed wild-type
(GFP-PHETA1WT) and mutant (GFP-PHETA1R6C) GFP-tagged
PHETA1 in HeLa cells, along with hemagglutinin (HA)-tagged
OCRL. Surprisingly, we found that HA-OCRL was co-
immunoprecipitated by both wild-type and mutant PHETA1
(Fig. 1G). This suggests that the R6C mutation might disrupt
PHETA1 protein function in a manner that does not affect OCRL
binding. Since the in vivo functions of PHETA1 and its close
homolog, PHETA2, were still unknown, we used zebrafish as the
experimental system to determine the roles of PHETA1/2 in the
context of a vertebrate organism.
Identification and CRISPR-Cas9 targeting of zebrafish
pheta1 and pheta2
We identified two PHETA1/2 homologs in zebrafish using in silico
sequence searches (see Materials and Methods). We refer to them as
Pheta1 (encoded by si:ch211-193c2.2) and Pheta2 (encoded by
zgc:153733). All known protein domain structures are conserved
between human and zebrafish proteins, including the F&H motif
(site of OCRL binding) (Fig. 2A). Like human PHETA1, Pheta1
(but not Pheta2) contains the PPPxPPRR motif for PACSIN2
binding. The neighboring genes of the human PHETA1 (SH2B3)
and zebrafish pheta1 (sh2b3) are also homologous, indicating that
the loci are syntenic and suggesting that zebrafish pheta1 is the most
likely ortholog of PHETA1 (Fig. 2B). The zebrafish pheta2 locus
Fig. 1. Identification of ade novomutation in humanPHETA1. (A) Images of the UDPpatient, presenting with facial asymmetry, concave nasal ridge andmalar
flattening. Radiograph (right) reveals mild asymmetry of the skull. (B) Radiographs depict scoliosis (arrowhead in left image) and clinodactyly of fourth and fifth
digits on both hands (arrowheads in middle and right images). (C) Whole-exome sequencing was performed on both parents and the fraternal twin of the UDP
patient. ‘N’ denotes not affected and ‘Y’ denotes affected. The arrow labeled ‘P’ identifies the UDP patient (UDP_5532). ‘+’ indicates the presence of a normal
allele, thus marking p.R6C as a heterozygous mutation. (D) COBALT multiple alignment of partial protein sequences of PHETA1 orthologs. The conserved
arginine residue is highlighted in red, and amino acid residues that differ from the sequence of the human PHETA1 protein are highlighted in green. The arginine
residue is highly conserved across multiple species. (E) Relative quantification of mRNA expression in the patient cells showing that the expression of PHETA1 is
not significantly different from that in controls. Error bar represents s.d. from six replicates. (F) 3-D structure of the human PHETA1 protein showing the PH domain
(green) with a four-stranded N-terminal and three-stranded C-terminal β-sheet with a helix (orange). The conserved arginine amino acid (Arg19 in the
PHETA1 long isoform, yellow) is far from the F&Hmotif (magenta); however, it stabilizes the folded domain around theC-terminal helix. (G) GFP-tagged full-length
WT PHETA1 or PHETA1R6C were expressed in HeLa cells and tested for interaction with full-length HA-tagged OCRL1. Bound proteins detected by western
blotting with the indicated antibodies. ‘IP: anti-GFP’ refers to the anti-GFP antibody-bound fraction; ‘Total’ represents the total cell lysate.
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lacked obvious synteny with either the human PHETA1 or PHETA2
loci (three neighboring genes examined; Fig. 2C). Based on overall
amino acid sequence similarity and phylogenetic distance (see
Materials and Methods), zebrafish Pheta1 is more similar to
mammalian PHETA1/2 (57.3% and 48.9% similarity to human
PHETA1 and PHETA2, respectively), whereas Pheta2 is more
divergent (44.2% and 39.2% similarity, respectively) (Fig. 2D).
To determine the functions of pheta1 and pheta2 in vivo, we
generated mutant alleles of pheta1 and pheta2 utilizing CRISPR-
Cas9 genome engineering (Gagnon et al., 2014; Jao et al., 2013)
(Fig. 2E). Genomic DNA sequencing showed that the pheta1vt2
allele contains a 38 bp deletion after the start codon of pheta1,
resulting in frameshift and predicted premature translational
termination, suggesting that this is likely a null allele
(Fig. 2E,G). The pheta2vt3 allele contains an 11 bp deletion in
exon 3 of pheta2, also resulting in a frameshift and predicted
premature translational termination, suggesting that this is also a
null allele (Fig. 2F,H). Sequencing of purified cDNA from
pheta1vt2 and pheta2vt3 homozygous animals ( pheta1−/− and
pheta2−/−) confirmed the incorporation of the 38 bp and 11 bp
deletion in the pheta1 and pheta2 transcript, respectively. Using
RNA sequencing (RNA-seq), we found no significant differences
in the amount of pheta1 or pheta2 transcripts among wild-type
(WT), pheta1−/− or double mutant (dKO) animals, suggesting that
the CRISPR-induced mutations do not induce nonsense-mediated
decay of pheta1/2 (Fig. 2I). RT-PCR with primers flanking the
CRISPR-Cas9 target site showed that pheta1 and pheta2 mRNA
were spliced correctly in the respective mutants, and no splice
variants were detected (Fig. 2J,K).
Zygotic pheta1−/− and pheta2−/− animals were viable and fertile,
with no external abnormalities during development (not shown).
pheta1 and pheta2 transcripts were detected from before zygotic
genome activation (one-cell and 512-cell stages) and were present
during early development [1-3 days post-fertilization (dpf )] (Fig.
S1). The early expression indicates that pheta1 and pheta2 are
maternally inherited, and the maternal transcript might compensate
for the loss of zygotic transcripts during the early stages of
development. We, therefore, focused on the maternal-zygotic
pheta1−/−, pheta2−/− and dKO animals (progeny from
homozygous mutant mothers), which lacked functional maternal
and zygotic transcript during development. We found that maternal-
zygotic pheta1−/−, pheta2−/− and dKO animals were viable and fertile
as well, with no external abnormalities during development.
Therefore, pheta1 and pheta2 are not required for viability and
fertility in zebrafish. Maternal-zygotic mutant animals were used for
all subsequent studies except for oculomotor function assays, in
which zygotic mutants were tested.
Loss of pheta1 and pheta2 impairs fluid-phase endocytosis
Previous findings in ocrl-deficient zebrafish and the UDP patient
phenotypes suggested that pheta1/2 might regulate endocytosis in
the renal system (Oltrabella et al., 2015). We examined renal
Fig. 2. Homology and CRISPR-Cas9 targeting of zebrafish pheta1 and pheta2. (A) The domain structures of human PHETA1, human PHETA2, and the
zebrafish PHETA homologs Pheta1 and Pheta2. The PH domain, coiled-coil domain, PPPxPPRR motif and OCRL binding site are highlighted. Like human
PHETA2, zebrafish Pheta2 lacks the PPPxPPRR motif. (B,C) Genomic organization of human PHETA1 (B) and PHETA2 (C) and their respective homologs in
mouse and zebrafish. (D) Phylogenic tree of PHETA proteins. Units indicate the number of amino acid substitutions per site. (E,F) The diagrams on the top
illustrate the genomic structures of pheta1 and pheta2, with the guideRNA (gRNA) target markedwith the asterisk. Green arrows indicate the primers for RT-PCR.
Sequences at the bottom show the gRNA target (underlined) associated with the protospacer adjacent motif (PAM; boxed letters), and the sequencesmutated by
CRISPR-Cas9 (blue). (G,H) CRISPR-mediated mutations result in reading frame shifts, causing aberrant protein sequences (gray regions) and premature
termination of the protein sequences for Pheta1 (G) and Pheta2 (H). The start of frameshift mutation is indicated by the red lines. (I) Normalized counts of pheta1
and pheta2 transcripts. (J,K) RT-PCR amplification of pheta1 (J) and pheta2 (K) complementary DNA (cDNA) from 4 dpf WT, pheta1−/− and pheta2−/− animals,
using the primer pairs indicated in E and F. Two lanes from two separate pools of animals are shown for each genotype. No alternative splice forms were detected
in the mutants. Expected sizes for pheta1: 326 bp (WT and pheta2−/−) and 288 bp (pheta1−/−). Expected sizes for pheta2: 825 bp (WT and pheta1−/−)
and 814 bp (pheta2−/−).
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endocytosis in the zebrafish, utilizing an established assay in which
fluorescent tracers were injected into the common cardinal vein
(CCV), followed by filtration and reabsorption into the renal tubular
cells lining the pronephric kidney, commonly referred to as the
pronephros (Anzenberger et al., 2006; Drummond et al., 1998;
Elmonem et al., 2017; Oltrabella et al., 2015). Endocytic uptake into
the renal tubular cells can then be analyzed using fluorescent
microscopy. We first tested fluid-phase endocytosis and
micropinocytosis, using 10 kDa fluorescent dextran as the tracer
(Li et al., 2015). Animals were injected at 3 dpf and then categorized
into three groups: high uptake, low uptake or no uptake (Fig. 3A).
The pheta1 heterozygous (pheta1+/−) and homozygous (pheta1−/−)
animals showed a trend of reduced tracer uptake, compared to the
WT control animals, but the difference did not reach statistical
significance (Fig. 3B) (Chi-square test; sample sizes are shown in the
figure). The dKO animals, however, exhibited a significant reduction
in tracer uptake compared to WT controls (P=0.0085). This suggests
that pheta1 and pheta2 acted redundantly in fluid-phase endocytosis,
such that endocytic deficit was only observed when both proteins
were depleted.
To verify that the reduction of 10 kDa dextran uptake in the dKO
animals was a fluid-phase endocytosis-specific defect, and not due
to the disruption of the glomerular filtration barrier, we tested
glomerular filtration in the pheta1−/− and dKO animals by injecting
500 kDa dextran. The 500 kDa dextran is too large to pass through a
normally functioning glomerular filtration barrier. Therefore, it is
expected to remain in the bloodstream. As shown in Fig. 3C,
the 500 kDa dextran was retained in the bloodstream in both the
pheta1−/− and dKO animals at 24 h post-injection (hpi), like in
the WT controls. Together, these results show that pheta1/2 are
required specifically for fluid-phase endocytosis in the renal organ.
Consistent with the in vitro findings that OCRL and PHETA1/2
physically and functionally interact during endosomal trafficking, we
found that reduction of zebrafish ocrl gene function significantly
exacerbated the fluid-phase endocytosis deficits in dKO animals. To
inhibit ocrl function, we used an ocrl anti-sense morpholino (MO)
that had been validated by ocrl mRNA rescue and phenotypic
similarity to ocrl germline mutants (Coon et al., 2012). To test fluid-
phase endocytosis, ocrl MO was injected at the one-cell embryonic
stage, and then 10 kDa dextran was injected into the CCV at 3 dpf.
Sample sizes are as indicated in Fig. 3D. Injection of 5 ng/nl ocrlMO
in the WT animals resulted in severe reduction in dextran uptake,
consistent with the previous finding that ocrl deficiency resulted in
impaired fluid-phase endocytosis (Oltrabella et al., 2015). Injection
of 4 ng/nl ocrl MO in WT animals resulted in a partial reduction in
dextran uptake. The same ocrl MO concentration, however, resulted
in a more severe reduction in dextran uptake in dKO animals (Chi-
square test;P<0.0001) (Fig. 3D). This suggests that ocrl and pheta1/2
functionally interact in zebrafish to enable fluid-phase endocytosis.
Interestingly, although ocrl is required for receptor-mediated uptake
of the receptor-associated protein (RAP) (Anzenberger et al., 2006;
Oltrabella et al., 2015), we found no significant differences among
WT, pheta1−/− and dKO animals in RAP endocytic uptake (Chi-
square test; sample size shown in figure) (Fig. 3E). Together, these
results indicate that pheta1/2 are only involved in a subset of the
endocytic functions of ocrl, specifically fluid-phase endocytosis.
Loss of pheta1/2 disrupts ciliogenesis in the pronephros
Several in vitro studies have described defects in ciliogenesis after
OCRL depletion, and it has been suggested that OCRL regulates
protein trafficking to the cilia in a Rab8/PHETA1-dependent
manner (Coon et al., 2012; Luo et al., 2012; Rbaibi et al., 2012).
To determine if depletion of pheta1 and/or pheta2 affect
ciliogenesis or cilia maintenance in vivo, we analyzed the cilia in
the pronephros of 3 dpf larvae (Fig. 3F-K′). We found that dKO
animals had shorter and fewer cilia, similar to the phenotype seen in
ocrl-deficient fish (Fig. 3L-O) (Oltrabella et al., 2015). In the dKO,
cilia length was reduced in the anterior pronephros (one-way
ANOVA with Holm-Sidak post-test; WT, n=15; pheta1−/−, n=11;
dKO, n=10; P=0058) (Fig. 3F-H′), and cilia number and length were
both reduced in the posterior pronephros (one-way ANOVA with
Holm-Sidak post-test; WT, n=20; pheta1−/−, n=11; dKO, n=12;
P=0.0213 for cilia number, P<0.0001 for cilia length) (Fig. 3I-K′)
(Oltrabella et al., 2015). Cilia diameter was not analyzed (due to the
resolution limitations of light microscopy). Since dKO animals
exhibited a similar cilia phenotype to that of the ocrl mutants, this
further supports the hypothesis that OCRL and PHETA proteins are
involved in the same pathway.
We next examined if there was a potential ciliary deficit in other
ciliated organs, including the inner ear (macula and crista), the
olfactory placode and the lateral line. We found no disruption of
ciliogenesis or cilia maintenance in these tissues analyzed in
pheta1−/− and dKO animals (Fig. S2). We also examined the outer
segments of photoreceptors, which are specialized cilia that
originate from the apical-most region of the inner segment.
Staining with rod and cone photoreceptor markers did not reveal
any differences among WT, pheta1−/−, pheta2−/− and dKO animals
(Fig. S2). This suggests that the role of pheta1/2 in ciliogenesis is
restricted to the pronephros.
pheta1/2 is not required for oculomotor function
The UDP patient was born with multiple visual complications,
including deficits with oculomotor function (e.g. congenital
exotropia, amblyopia, nystagmus). To test whether a deficiency in
PHETA1/2 contributes to oculomotor deficits, we analyzed the
optokinetic response (OKR) in pheta1/2 mutants. Zygotic mutants
were used to allow for direct comparisons between siblings, which
minimized the confounding effects of genetic background-
associated variability in behavioral assays (Gorissen et al., 2015;
Lange et al., 2013). OKR is a gaze stabilization response that
utilizes the extraocular muscles to stabilize an image on the retina in
response to visual motion. It is necessary for maintaining optimal
visual acuity and is conserved in all vertebrates (Huang and
Neuhauss, 2008). In zebrafish, OKR matures at 3-4 dpf but is
commonly tested at 5-6 dpf to ensure the complete development of
involving neural and extraocular systems (Easter and Nicola, 1997;
Huang and Neuhauss, 2008). We tested 5-6 dpf animals inside a
circular arena with projections of moving black and white gratings,
and the eye positions were video-recorded (Fig. S3A). The grating
directions alternated clockwise and counter-clockwise at different
contrasts at 3-s periodicity. We tested siblings in the progeny of
pheta1/2 double heterozygous animals ( pheta1+/–;pheta2+/–), and
the eye velocity in response to the moving gradients was analyzed.
No significant differences in eye velocity were observed among
WT, pheta1−/−, pheta2−/− or dKO siblings (two-way ANOVAwith
Holm-Sidak post-test; WT, n=34; pheta1−/−, n=18; pheta2−/−, n=8;
dKO, n=10). We then investigated the correlation of velocity and
angle between the left and right eyes (Fig. S3B,C). A reduced
correlation would suggest strabismus, in which the eyes do not
properly align with each other. No significant differences in angle or
velocity correlation were observed among WT, pheta1−/−, pheta2−/−
or dKO siblings (two-way ANOVAwith Holm-Sidak post-test; WT,
n=34; pheta1−/−, n=18; pheta2−/−, n=8; dKO, n=10). Thus, the
deficiency in pheta1/2 did not affect oculomotor function.
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Loss of pheta1/2 disrupts craniofacial morphogenesis
As mentioned previously, PHETA1 and PHETA2 were previously
found to be involved in the sorting of lysosomal hydrolases
in vitro. Disruption of this pathway in vivo could give rise to
craniofacial abnormalities, as seen in lysosomal storage
disorders such as MLII (Cathey et al., 2010; Koehne et al.,
2016; Kudo et al., 2006). Therefore, we investigated whether
craniofacial development was affected by the loss of pheta1/2.
Fig. 3. Loss of pheta1/2 disrupts fluid-phase endocytosis and ciliogenesis in the pronephros. (A,B) Pronephros uptake of Alexa Fluor 488-10 kDa dextran
in 3 dpf larvae. (A) Animals were categorized as having high, low or no uptake (WT images are shown). The pronephric tubules are indicated by white dashed
lines. Scale bars: 100 µm. (B) Comparison of 10 kDa dextran uptake between genotypes. (C) Representative images of animals injected with 500 kDa dextran.
Scale bars: 200 µm. (D) WT and dKO animals injected with ocrl MO at the one-cell stage, then 10 kDa dextran at 3 dpf. (E) Pronephros uptake of RAP-Cy3 at
3 dpf. (F-K′) Representative confocal images of cilia in the pronephros of WT, pheta1−/− and dKO animals. Cilia were labeled with anti-acetylated α-tubulin
(green), basal bodies were labeled with anti-γ tubulin (red), and nuclei were labeled with toto-3 or DAPI (blue). Scale bars: 25 µm. Areas within the white dashed
boxes in F,G,H,I,J,K are magnified in F′,G′,H′,I′,J′,K′. Arrowheads indicate examples of shorter cilia in dKO animals. Scale bars: 10 µm. (L-O) Quantification of
cilia morphology in 3 dpf larvae. Graphs show the cilia number (L) and length (M) in the anterior pronephros, and the cilia number (N) and length (O) in the
posterior pronephros. Five cilia were selected from each animal for cilia length measurements. Error=s.e.m. *P<0.05, **P<0.01, ****P<0.0001.
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WT, pheta1−/−, pheta2−/− and dKO animals at 6 dpf were stained
with Alcian Blue and Alizarin Red to label the cartilage and bone,
respectively. Representative lower jaw images of the WT and
mutants are shown (Fig. 4A,B). We did not observe any loss of
cartilage or bone structures. There is a reduction in ceratohyal
ossification (arrowheads in Fig. 4B), with pheta2−/− and dKO
Fig. 4. Loss of pheta1/2 disrupts craniofacial development. (A,B) Alcian Blue and Alizarin Red staining in 6 dpf animals. Structures are as indicated in the
leftmost images. (A) Ventral view of the lower jaw. Representative images from each genotype are shown. Images are quantified in panels C-H. Scale bars:
200 µm. (B) Flat-mount preparations of the lower jaw at 6 dpf. Arrowheads point to where osteogenesis occurs within the ceratohyal cartilage. The number of
animals imaged with displayed phenotype is shown in the lower-left corner of each image. Scale bars: 100 µm. (C-H) Morphological measurements of 6 dpf
larvae, with the measured distance/area highlighted in red in the above schematics. bsr, brachiostegal ray; ch, ceratohyal; en, entopterygoids; hs, hyosymplectic;
m, Meckel’s cartilage; op, opercle; pq, palatoquadrate. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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animals lacking the ceratohyal bone collar at 7 dpf (Fig. S4A). This
suggests a developmental deficit in the ceratohyal (explored
further in the next section).
Overall, the mutants exhibited shorter and narrower jaws. To
quantitate this difference, we used a set of morphological parameters
previously utilized to describe craniofacial phenotypes in zebrafish
larvae, namely cranial distance, ceratohyal distance, ceratohyal
length, Meckel’s area, jaw width and jaw length (Fig. 4C-H) (de
Peralta et al., 2016). Together, thesemeasurements informed us about
the overall length and proportions of the head, as well as the growth of
an individual cartilage structure (ceratohyal). In the pheta2−/− and
dKO animals, we found a significant reduction in all of the above
parameters. In the pheta1−/− animals, only the Meckel’s area, jaw
width and jaw length were reduced (one-way ANOVA with Holm-
Sidak post-test; WT, n=11; pheta1−/−, n=16; pheta2−/−, n=16; dKO,
n=16; cranial distance: P<0.0001 for WT versus pheta2−/− and WT
versus dKO; ceratohyal distance: P<0.0001 for WT versus pheta2−/−,
P=0.0006 for WT versus dKO; ceratohyal length: P=0.0066 for WT
versus pheta2−/−, P<0.0001 for WT versus dKO; Meckel’s area:
P=0.0496 for WT versus pheta1−/−, P<0.0001 for WT versus
pheta2−/−, P<0.0001 for WT versus dKO; jaw width: P=0.0084 for
WT versus pheta1−/−, P<0.0001 for WT versus pheta2−/− and WT
versus dKO; jaw length: P=0.0132 for WT versus pheta1−/−,
P=0.0057 for WT versus pheta2−/−, P=0.0003 for WT versus dKO)
(Fig. 4C-H). Depletion of both pheta1 and pheta2 had an additive
effect, indicating functional redundancy during craniofacial
development.
Loss of pheta1/2 disrupts chondrocyte differentiation
The craniofacial morphogenesis defects observed in pheta1/2
mutants suggest an underlying developmental abnormality. To
test this, we first examined the morphology of chondrocytes, which
assume a more elongated shape during convergent extension
(Kimmel et al., 1998; Le Pabic et al., 2014). If there is a delay in
early chondrocyte differentiation, the chondrocytes can persist with
more rounded morphology, with a long-axis/short-axis ratio closer
to one (Flanagan-Steet et al., 2009; Le Pabic et al., 2014; LeClair
et al., 2009). To test this, we measured the long-axis/short-axis ratio
of individual cells in flat-mount preparations of the lower jaw
(Figs 4B and 5A). One ceratohyal cartilage per animal was imaged,
and all cells within the ceratohyal cartilage were measured manually
in the Fiji software.We found significant reduction in the elongation
of chondrocytes (lower ratio) in the pheta1−/−, pheta2−/− and dKO
animals, suggesting a delay in chondrocyte differentiation (Fig. 5B)
(one-way ANOVA with Holm-Sidak post-test; WT, n=106 cells
from three animals; pheta1−/−, n=137 cells from four animals;
pheta2−/−, n=127 cells from three animals; dKO, n=152 cells from
four animals; P=0.0439 forWT versus pheta1−/−,P=0.0178 forWT
versus pheta2−/−, P=0.0167 for WT versus dKO).
Next, we examined the expression of various markers that
characterize the sequential stages of development. During
chondrocyte differentiation, there is a decline in TGF-β-signaling,
and thus a decrease in Smad2/3 and Sox9 transcriptional regulators.
At the same time, there is a coordinated change in the extracellular
matrix protein composition as the chondrocytes mature (Flanagan-
Steet et al., 2016; Goldring et al., 2006). Type II collagen (Col2,
encoded by col2a1a) is one of the earliest markers of chondrocyte
differentiation (Goldring et al., 2006). Col2 expression decreases as
chondrocytes become more mature at 4 dpf (Flanagan-Steet et al.,
2016). Immunostaining for Col2 at 4 dpf showed that pheta2−/− and
dKO animals exhibited a striking increase in Col2 expression
compared to WT controls, while the pheta1−/− animals had a
modest increase (Fig. 5C-E) (one-way ANOVA with Holm-Sidak
post-test; n=10 animals per genotype; ceratohyal: P=0.0498 for WT
versus pheta1−/−, P<0.0001 for WT versus pheta2−/− and WT
versus dKO; Meckel’s: P=0.0001 for WT versus pheta1−/−,
P<0.0001 for WT versus pheta2−/− and WT versus dKO). This is
consistent with our morphological measurements, in which
pheta2−/− and dKO animals exhibited a more severe deficit in
overall craniofacial development compared to pheta1−/− animals.
Given the upregulation of Col2, we asked whether other markers
of chondrocyte differentiation were affected by the loss of pheta1/2
(Flanagan-Steet et al., 2016). We examined two later-stage markers,
acana and dcn, which encode the protein cores (Aggrecan and
Decorin) of the chondroitin sulfate proteoglycan extracellular
matrix. For earlier-stage markers, we looked at col2a1a (encodes
Col2) and sox9a (encodes Sox9). The Sox9 transcription factor is
required for early chondrocyte differentiation, but sustained Sox9
expression can inhibit later stages of development (Akiyama et al.,
2004; Furumatsu et al., 2005; Yan et al., 2002). Using RNA-seq,
WT transcript levels were compared to those from pheta1−/− and
dKO (5 dpf ). Two-way ANOVA with Holm-Sidak post-test was
used for statistical analysis (n=3 pools of animals for each
genotype). If the pheta1/2 mutants have more immature
chondrocytes, then they would have lower expression of acana/
dcn and higher levels of col2a1a/sox9a. We found that the
expression of acana and dcn was not significantly changed in the
pheta1−/− and dKO groups, compared to WT (Fig. S4B,C). There
was a significant increase in col2a1a expression in pheta1−/− and
dKO groups, consistent with our Col2 immunostaining findings
(Fig. S4D) (P=0.01 for WT versus pheta1−/− and WT versus dKO).
This indicates that increased levels of Col2 may be due to increased
col2a1a mRNA levels. We found no significant changes in sox9a
transcript levels (Fig. S4E). In situ hybridization also revealed no
significant differences in sox9a expression in the lower jaw among
4 dpf WT, pheta1−/−, pheta2−/− and dKO animals (Fig. S4F).
Together, we find evidence of delayed chondrocyte differentiation, as
evidenced by rounded cell morphology and increased expression of
Col2/col2a1a. The fact that other markers of chondrocyte
differentiation (acana, dcn and sox9a) were unaffected suggests that
loss of pheta1/2 does not globally alter the differentiation program.
pheta1/2 regulates Col2 expression through cathepsin K
Extracellular matrix remodeling and homeostasis during
chondrogenesis and osteogenesis are dependent on the function of
proteolytic enzymes, including cysteine proteinases (known as
cathepsins) and metalloproteinases (Holmbeck and Szabova, 2006;
Yasuda et al., 2005). For example, dysregulation of cathepsin K
causes craniofacial abnormalities in zebrafish models of the
lysosomal storage disorder MLII (Flanagan-Steet et al., 2018;
Petrey et al., 2012). Since PHETA1/2 was found to be involved in
the transport of lysosomal hydrolases from the TGN to the
endosomes, we hypothesized that cathepsin dysregulation caused
by a deficiency in pheta1/2 might also cause deficits in craniofacial
development. To test this, animals were treated with a cathepsin K-
specific inhibitor, odanacatib (Od), at 3 dpf and then collected and
immunostained for Col2 at 4 dpf (Flanagan-Steet et al., 2018; Gauthier
et al., 2008). Od significantly reduced Col2 in the dKO animals at both
25 nM and 50 nM concentrations (Kruskal–Wallis test with Dunn’s
post-test;WT, n=5;WT+50 nMOd, n=3; dKO, n=9; dKO+25 nMOd,
n=5; dKO+50 nMOd, n=5; ceratohyal: adjustedP=0.0403 and 0.0323
for 25 nM and 50 nM Od, respectively; Meckel’s: adjusted P=0.0020
and 0.0176 for 25 nM and 50 nM Od, respectively), while not
affecting Col2 levels in WT (Mann–Whitney U-test) (Fig. 6A-D).
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Interestingly, therewas no significant Col2 reduction in pheta1−/− and
pheta2−/−, indicating that pheta1 and pheta2 may be able to
compensate for one another in regulating cathepsin K activity
(Mann–Whitney U-test; pheta1−/−, n=6; pheta1−/−+50 nM Od,
n=5−; pheta2−/−, n=5; pheta2−/−+50 nM Od, n=5.) (Fig. S5).
We then tested whether Od could rescue the skeletal phenotypes
caused by pheta1/2 deficiency. To do this, we performed lower-jaw
morphological measurements of 4 dpf WT and dKO animals with
and without exposure to 50 nM Od from 3 dpf to 4 dpf (Fig. 6E).
Statistical analyses were performed with one-way ANOVA and
Holm-Sidak post-test (WT, n=14; WT+50 nM Od, n=15; dKO,
n=14; dKO+50 nM, n=14). Similar to what was found in 6 dpf
animals (Fig. 4C-H), dKO animals had significantly smaller
craniofacial structures, compared to WT (Fig. 6F-L). Specifically,
cranial distance (P=0.0190), ceratohyal distance (P=0.0165),
ceratohyal length (P=0.0224), ceratohyal thickness (P=0.0017)
and Meckel’s area (P=0.0025) were all reduced in dKO animals,
compared to WT. These metrics were all rescued by Od (P>0.05 for
WT versus dKO+50 nM Od). Jaw width was the only metric not
rescued by Od (P<0.0001 between WT and dKO, P=0.0009
between WT and dKO+50 nM Od). Interestingly, Od increased jaw
length in dKO but not in WT (P=0.0021 for WT versus dKO treated
with Od). The increase in jaw length is not caused by a substantial
whole-specimen soft-tissue defect, which was not observed.
Fig. 5. Loss of pheta1/2 disrupts chondrocyte
maturation. (A) Ceratohyal cartilage, stained with
Alcian Blue in flat-mount preparation. Scale bars:
50 µm. (B) Chondrocyte morphology analysis in
ceratohyal cartilage (within a 200 µm2 area).
(C) Top row: Z-projection ventral view of larvae
immunostained for Col2 (green). Nuclei are labeled
with DAPI (blue). Scale bars: 100 μm. Middle row:
higher-magnification Z-projection images of
corresponding ceratohyal cartilage. Scale bars: 25
μm. Bottom row: higher-magnification single optical
section images of corresponding ceratohyal cartilage,
depicting extracellular secretion of type II collagen.
Scale bars: 25 µm. (D,E) Quantification of mean
fluorescence intensity in the ceratohyal (D) and
Meckel’s cartilage (E) in 5 dpf larvae. *P<0.05,
***P<0.001, ****P<0.0001.
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Fig. 6. Craniofacial deficits are rescued by Od-mediated inhibition of cathepsin K. (A-D) Mean fluorescence intensity of Col2 immunostaining in the
ceratohyal (WT in A, dKO in B) and Meckel’s cartilage (WT in C, dKO in D) of 4 dpf larvae with and without Od treatment. (E) Representative images of larvae
stained with Alcian Blue. Scale bars: 200 µm. (F-L) Craniofacial morphological measurements at 4 dpf. The measured parameters are highlighted in red in the
schematics. (M) In-gel analyses of BMV109, showing cathepsin activities in WT and pheta1/2 mutants at 4 dpf. Blue lines indicate the lane boundaries.
(N,O) Quantitation of the cathepsin K and cathepsin L bands from four experiments. Error=s.e.m. ch, ceratohyal; Ctsk, cathepsin K; Ctsl, cathepsin L; m, Meckel’s
cartilage. *P<0.05, **P<0.01, ****P<0.0001.
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Together, these results show that the craniofacial deficits in dKO
animals can largely be rescued by reducing cathepsin K activity
with Od.
Next, we asked if pheta1/2 affects the level of cathepsin K
activity. We utilized a cathepsin-specific activity-based probe
(ABP), BMV109, to measure global (whole-animal) cysteine
cathepsin activity in both WT and pheta1/2 mutants (Flanagan-
Steet et al., 2018; Verdoes et al., 2013). The animals were treated at
3 dpf, a period when certain cathepsin activities (e.g. cathepsin K)
typically begin to wane inWT animals (Flanagan-Steet et al., 2018).
pheta1/2 deficiency did not significantly impact cathepsin L
activity, the most prominent cathepsin activity at this stage
(Kruskal–Wallis test with Dunn’s post-test; n=5 for all genotypes)
(Fig. 6M,N). Cathepsin K activity was also not significantly changed,
but there was a trend toward increased activity in pheta2−/− animals
and increased variability in dKO animals (Kruskal–Wallis test with
Dunn’s post-test; n=5 for all genotypes) (Fig. 6M,O). Together, these
results indicate that pheta1/2 may have a specific role in regulating
cathepsin K in the cartilage, rather than a global role in cathepsin K
activity.
pheta1R6C exerts a dominant-negative effect on craniofacial
development
One striking clinical feature identified in the UDP patient is
abnormal craniofacial development. The patient presented with
coarse facial features and facial asymmetry. She also had shorter feet
and palms, as well as abnormal dental morphology and
malocclusion (Table 1). These phenotypes could be due to
cartilage development deficits caused by PHETA1
haploinsufficiency or dominant-negative effects of the R6C allele.
If pheta1R6C was non-functional or partly functional, then ectopic
expression of Pheta1R6C in pheta1+/– or pheta1−/− backgrounds
should have no effect or partially improve craniofacial development.
However, if pheta1R6C was dominant negative, then ectopic
expression of pheta1R6C should worsen craniofacial development
in the same backgrounds. Thus, we generated two zebrafish
transgenic lines, one that ubiquitously expressed an EGFP-
Pheta1R6C fusion protein [Tg(ubb:pheta1_R6C-GFP), referred to
as Tg(R6C)], and another that expressed EGFP fused with WT
Pheta1 [Tg(ubb:pheta1-GFP), referred to as Tg(WT)] (Fig. 7A).
Confocal imaging confirmed the broad expression of Tg(R6C) and
Tg(WT) (Fig. 7B).
We then tested whether Tg(R6C) and Tg(WT) affected
craniofacial development. To mimic the genetic background of
the UDP patient, which is heterozygous for the R6C allele, we
analyzed the effects of Tg(R6C) and Tg(WT) in the pheta1
heterozygous ( pheta1+/−) background (Fig. 7C-E). We also
analyzed the effects of Tg(R6C) and Tg(WT) in the pheta1−/−
background to test whether there could be an effect in the absence of
functional pheta1 (Fig. 7D′,E′). We found that, in both pheta1+/–
and pheta1−/− backgrounds, Tg(R6C) significantly reduced jaw
width [two-tailed Student’s t-test; pheta1+/−, n=15; Tg(R6C);
pheta1+/−, n=16; pheta1−/−, n=13; Tg(R6C);pheta1−/−, n=15;
P<0.0001 for pheta1+/– background, P=0.0004 for pheta1−/−
background]. Tg(WT) had no significant effects on jaw width in
the pheta1+/– background [two-tailed Student’s t-test; pheta1+/−,
n=15; Tg(WT); pheta1+/−, n=15; pheta1−/−, n=13; Tg(WT);
pheta1−/−, n=15] and a weak negative effect in the pheta1−/−
Fig. 7. Pheta1R6C exerts a dominant-negative effect on craniofacial development in the partial or complete absence of Pheta1. (A) Outline of the
procedures for generating the Tg(R6C) and Tg(WT) transgenic lines. (B) Confocal images showing broad expression of Pheta1WT-GFP and Pheta1R6C-GFP
larvae in transverse cryosections, stained with anti-GFP (green) and DAPI (blue). A control larva with no transgene expression (Tg-Negative) is shown for
comparison. Scale bars: 100 μm. (C-E′) Craniofacial measurements of 6 dpf larvae, with schematics shown in C. (D,E) Jaw width of pheta1+/– animals with and
without Tg(R6C) (D) and Tg(WT) (E) transgenes. (D′,E′) Jaw width of pheta1−/− animals with and without Tg(R6C) (D′) and Tg(WT) (E′) transgenes. *P<0.05,
***P<0.001, ****P<0.0001. (F) Summarymodel. At the subcellular level, PHETA1/2 is known to interact with OCRL to regulate intracellular trafficking, ciliogenesis,
endocytosis and secretion. These cellular functions likely enable PHETA1/2 to facilitate renal and craniofacial development, with the latter further requiring
cathepsin K regulation. In humans, a deficiency in PHETA1 function potentially leads to abnormal development of the kidney and craniofacial structures. Other
functional impairments such as hearing and tongue movement may also be associated with abnormal cartilage or bone formation.
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background (P=0.0418). These results indicate that the R6C variant
likely acts on craniofacial development in a dominant-negative
manner. Interestingly, Pheta1R6C impacted the craniofacial
morphological parameters that were affected by the loss of both
pheta1 and pheta2 ( jaw width, Fig. 4G), but not those that were
only affected by the loss of pheta2 (cranial distance and ceratohyal
length, Fig. 4C,E; Fig. S6) [two-tailed Student’s t-test; pheta1+/−,
n=15; Tg(R6C);pheta1+/−, n=16; pheta1−/−, n=13; Tg(R6C);
pheta1−/−, n=15]. This suggests that Pheta1R6C may have a
relatively limited capacity to interfere with Pheta2 function.
DISCUSSION
The regulation of endocytic trafficking is essential for the
development and function of an organism. In this study, we
present the first in vivo investigation of the functions of PHETA
proteins, which are membrane adaptor proteins for the Lowe
syndrome causative protein, OCRL. Using zebrafish as the
experimental system, we found that pheta1 and pheta2 were
necessary for renal fluid-phase endocytosis and ciliogenesis.
Furthermore, we found that loss of pheta1/2 impaired craniofacial
development and altered the composition of the cartilage
extracellular matrix. Evidence also indicates that cathepsin K
dysregulation contributes to the craniofacial deficits caused by
pheta1/2 deficiency.
These findings provide insight into the possible
pathophysiology of an individual with a de novo R6C mutation
in PHETA1. The patient presented with renal and craniofacial
phenotypes that were similar to the observed phenotypes in
pheta1/2 mutant zebrafish, suggesting that deficiency in PHETA1
contributes to disease. Using transgenic expression in zebrafish,
we found that the R6C allele acted in a dominant-negative manner.
Together, our results reveal the essential physiological and
developmental roles of PHETA proteins and indicate cathepsin
proteases as potential targets for PHETA-associated diseases. A
summary model is shown in Fig. 7F.
The roles of pheta1 and pheta2 in renal fluid-phase
endocytosis and ciliogenesis
Loss of pheta1/2 affected the renal fluid-phase endocytosis (of
10 kDa dextran substrate), but not receptor-mediated endocytosis
(of RAP) (Anzenberger et al., 2006). In contrast, loss of ocrl in
zebrafish resulted in a strong reduction in both types of endocytosis
(Oltrabella et al., 2015). Partial knockdown of ocrl in the dKO
animals exacerbated the fluid-phase endocytic deficit, indicating
that pheta1/2 and OCRL likely function in a common endocytic
pathway. These results suggest that pheta1/2 participates in only a
subset of the functions of OCRL in vivo. Likely, other F&H motif-
containing OCRL adaptor proteins such as APPL1 can partially
compensate for the loss of PHETA1/2 (Noakes et al., 2011;
Pirruccello et al., 2011; Swan et al., 2010).
The pronephros of dKO animals had fewer and shorter cilia,
similar to what was found in ocrl-deficient zebrafish (Oltrabella
et al., 2015). However, the ciliogenesis defect in dKO and ocrl−/−
animals likely does not account for the endocytosis deficits. First,
unabsorbed fluorescent dextran was normally excreted from the
cloacae in the dKO animals, indicating that there was no impairment
of cilia-directed fluid flow within the pronephros. Second, we did
not see the development of renal cysts in any of our pheta1/2
mutants, which is consistent with normal fluid flow. Lastly, even
mutants with severe ciliogenesis deficits (e.g. the double bubble
mutant) could endocytose dextran normally (Drummond et al.,
1998; Liu et al., 2007; Oltrabella et al., 2015). Thus, pheta1/2 likely
contributes to fluid-phase endocytosis independently of its role in
ciliogenesis.
A novel role for pheta1 and pheta2 in craniofacial
development
We identified a novel role for pheta1 and pheta2 in craniofacial
morphogenesis. Craniofacial development appeared to rely more on
pheta2, but depletion of both pheta1 and pheta2 resulted in an
additive effect, indicating that pheta1 plays a role as well. In pheta2−/−
and dKO animals, we observed features indicative of abnormal
chondrocyte differentiation, including abnormal chondrocyte
morphology, reduced ceratohyal ossification, changes in marker
gene expression and altered extracellular matrix composition (i.e.
increased Col2). As a first foray into the underlying molecular
mechanisms, we found that inhibition of cathepsin K using the
specific inhibitor Od significantly reduced Col2 protein levels in the
dKO animals and rescued most of the lower jaw morphological
deficits in the dKO animals. This indicates that overactive cathepsin
K activity may be the cause of abnormal craniofacial development.
Interestingly, we did not see a consistent global increase in
cathepsin K activity using an in vivo activity probe (BMV109),
indicating that the dysregulation of cathepsin K activity may stem
from changes in a subset of cells within craniofacial structures.
Alternatively, there may be clutch-to-clutch differences in
compensatory mechanisms to control cathepsin K activity. For
example, there may be variability in cystatin activity, which inhibits
cathepsin K (Vidak et al., 2019). Cathepsins also regulate growth
factor activity in the cellular microenvironment, which may result in
stochastic changes and more variability during the course of
development. Future studies might explorewhere active cathepsin K
resides as development progresses and how Col2 levels are
modulated by protease activity in pheta1/2 mutant animals. It was
previously shown that TGF-β signaling is enhanced by mislocalized
cathepsin K activity (Flanagan-Steet et al., 2016, 2018; Vidak et al.,
2019). Thus, the absence of pheta1/2 could lead to altered TGF-β
signaling, which may, in turn, mediate the abnormal craniofacial
morphogenesis.
Investigating the pathogenesis of the UDP patient’s disease
A primary motivation for understanding the in vivo function of
PHETA1/2 was the identification of a patient carrying a de novo
PHETA1 mutation. To the best of our knowledge, this patient was
the first reported case of human disease associated with PHETA1 or
PHETA2 mutation. Although the R6C mutation did not affect
interaction with OCRL, it did exert a dominant-negative effect on
craniofacial development, even in the absence of endogenous
pheta1. Since the R6C mutant can interact with OCRL, it may be
able to disrupt the function of OCRL complexes, analogous to how
the G59S mutation in dynactin subunit 1 (DCTN1) disrupts the
function of the dynein/dynactin complex (Lai et al., 2007).
Alternatively, since PHETA1 and PHETA2 can form homodimers
and heterodimers, the R6C mutant may bind to and interfere with
the normal functions of PHETA1 and PHETA2. Our hypothesis that
the R6C mutation resulted in a deficiency of PHETA1/2 function is
supported by the overlapping phenotypes between the patient and
our zebrafish mutants, specifically in craniofacial development and
renal function (Table 1).
When drawing comparisons between zebrafish and human
craniofacial phenotypes, it is important to note the relationships
between zebrafish lower-jaw elements and human jaw anatomy
(DeLaurier, 2019; Mork and Crump, 2015). The first pharyngeal
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arch (Meckel’s, palatoquadrate)- and second pharyngeal arch
(hyosymplectic, ceratohyal)-derived elements become the lower
jaw and craniofacial skeleton in both species. The Meckel’s
cartilage gives rise to part of the lower jaw and the inner ear,
whereas the ceratohyal gives rise to the styloid process and the
hyoid. With this in mind, the deficits we observed in Meckel’s and
ceratohyal cartilage could provide plausible explanations to some of
the UDP patient’s clinical presentations. Specifically, dental
abnormalities and hearing impairments may be linked to deficits
in the Meckel’s cartilage, whereas difficulty in tongue movements
could be caused by deficits in the hyoid, which is a ceratohyal-
derived structure (Fig. 7F).
Lastly, we note that the UDP patient has three other de novo
mutations considered less likely to be contributing to disease. One
variant in DnaJ heat shock protein family (Hsp40) member B5
(DNAJB5; NM_001135004: p.R419H) has inconsistent predictions
with SIFT and Polyphen, and occurs in a moderately conserved
amino acid, so it is unlikely that this causes the UDP patient’s
disease. A second variant, in uridine phosphorylase 1 (UPP1;
NM_003364:p.I117V), is seen in 12 normal individuals and is
predicted benign by SIFT and Polyphen, so it is unlikely to be
pathogenic. The third variant, is in plant homeodomain (PHD)-like
finger protein 6 (PHF6; NM_001015877.1: p.Leu244del), which
has been associated with X-linked Borjeson–Forssman–Lehmann
syndrome (BFLS; MIM #301900); one female patient has been
reported with a loss of function allele and X-inactivation (Turner
et al., 2004). X-inactivation studies in our patient showed a skewed
pattern, but an association with PHF6 was unlikely due to a lack of
phenotypic overlap with BFLS. Furthermore, the variant identified in
our patient, unlike a clear loss of function mutation reported in BFLS,
leads to an in-frame deletion with no splicing defect (Fig. S7).
Identification of additional patients carrying deleterious PHETA1
mutation will help to clarify which phenotypes are more closely
associated with PHETA1 deficiency in humans.
Conclusions
In conclusion, we have determined novel in vivo functions of the
OCRL adaptor proteins PHETA1 and PHETA2. Deficiency in
pheta1/2 resulted in impaired renal physiology and craniofacial
development in zebrafish, resembling the renal and craniofacial
phenotypes in a UDP patient carrying a dominant-negative allele of
PHETA1. The craniofacial deficits in zebrafish pheta1/2 mutants
were likely caused by a dysregulation of cathepsin K, which altered
the extracellular composition of craniofacial cartilages and
craniofacial morphogenesis. These results support the hypothesis
that PHETA1 mutation was contributory to disease, but further
studies with additional patients will be needed to determine the roles
of PHETA1/2 in human disease fully.
MATERIALS AND METHODS
Patient enrollment, consent and sample analysis
The patient (UDP.5532) was enrolled in the NIH UDP (Gahl et al., 2012,
2016, 2015) under the protocol 76-HG-0238, ‘Diagnosis and Treatment of
Patients with Inborn Errors of Metabolism and Other Genetic Disorders’,
which was approved by the Institutional Review Board of the National
Human Genome Research Institute. Written informed consent to publish
was obtained from the parents of the patient.
Patient-derived fibroblasts were cultured in high-glucose Dulbecco’s
modified Eagle medium (DMEM) supplemented with 15% fetal bovine
serum (FBS), non-essential amino acid solution, and penicillin-
streptomycin with L-glutamine (Thermo Fisher Scientific). Normal adult
human sex-matched dermal fibroblasts (ATCC PCS-201-012) were used as
controls. Cell cultures were checked regularly for contamination. RNAwas
isolated using an RNeasy Mini Kit (Qiagen), and first-strand cDNA was
synthesized by a high-capacity RNA to cDNA kit (Thermo Fisher
Scientific) according to the manufacturer’s protocol. For qRT-PCR,
primer pairs specific to the three common isoforms (NM_001177996.1,
NM_001177997.1 and NM_144671.4) of human PHETA1 (forward
primer, 5′-GAAGAGCGAGCTGAGGCTG-3′; reverse primer, 5′-
GTCACAGGTGGCGTAGAAGG-3′) and housekeeping gene POLR2A
(forward primer, 5′-CATGTGCAGGAAACATGACA-3′; reverse primer,
5′-GCAGAAGAAGCAGACACAGC-3′) were PCR amplified and
monitored using a CFX96 Touch Real-Time PCR detection system (Bio-
Rad). Relative expression of PHETA1 transcripts was normalized to the
expression of POLR2A and analyzed using standard delta delta Ct method.
qRT-PCR experiments were performed in accordance with the Minimum
Information for Publication of Quantitative Real-Time PCR Experiments
(MIQE) guidelines (Bustin et al., 2009). For splice site analysis of the
variant in PHF6 (NM_001015877.1:c.732_734del; p.Leu244del), we
amplified the patient cDNA using PHF6-specific primers flanking the
site of mutation and subcloned into a plasmid vector using TOPO-TA
cloning (Thermo Fisher Scientific), and sequenced according to the
manufacturer’s instructions. Recombinant colonies were picked up by
blue-white screening and extracted plasmids were sequenced using vector-
specific M13 primers.
Zebrafish husbandry
Zebrafish of both sexes and all agesweremaintained under a standard protocol
in accordancewith InstitutionalAnimal Care andUse Committee guidelines at
Augusta University, Virginia Tech and Greenwood Genetic Center. All
zebrafish used in this study were in a mixed background of AB and TLWT
lines (Zebrafish International Resource Center). Sex is not a relevant variable
for the stages being used (0-7 dpf), as laboratory zebrafish remain sexually
undifferentiated until 2 weeks of age (Maack and Segner, 2003; Wilson et al.,
2014). To prevent pigment formation for selected experiments, embryos were
transferred to embryo medium containing 0.003% 1-phenyl-2-thiourea (PTU;
Sigma-Aldrich) between 18 h post-fertilization (hpf) and 24 hpf.
Mutant and transgenic zebrafish lines
pheta1 (si:ch211-193c2.2, ZFIN ID: ZDB-GENE-041210-163,
Chromosome 5: 9,677,305-9,678,075) was identified by a BLAT search
using a human PHETA1 coding sequence against the UCSC zebrafish
genome database (Kent, 2002). pheta2 (zgc:153733, ZFIN ID: ZDB-
GENE-060825-273, Chromosome 3: 32,821,205-32,831,971) was
identified as a paralog of pheta1 in the Ensembl database (Zerbino et al.,
2018). Neighboring genes of pheta1/2 were identified using the UCSC
genome browser (Kent et al., 2002). Phylogenetic tree of PHETA proteins
was inferred using the Neighbor-Joining method in the MEGA X software
(Kumar et al., 2018). The evolutionary distances were computed using the
Poisson correction method. An in silico search for pheta1/2 paralogs was
performed, utilizing BLAST and the Comparative Genomics tool in the
Ensemble website (ensemble.org). No pheta1/2 paralogs were identified. A
search was performed on the UCSC genome database for potential syntenic
regions between human and zebrafish. In humans, PHETA1 is adjacent to
CUX2, SH2B3 and ATXN2, whereas PHETA2 is adjacent to NAGA, SMDT1
and NDUFA6. The genomic regions containing the zebrafish homologs of
these genes did not contain any additional PH domain-containing genes in
these regions. These findings support the idea that pheta1/2 are the only
zebrafish homologs of human PHETA1/2. Protein sequence similarity was
calculated using the AlignX module from the Vector NTI 9 software suite
(Invitrogen).
Mutants were generated using CRISPR-Cas9 genome engineering, as
previously described ( pheta1 target sequence, GGAGCTGAACGAGAG-
GAGTG; pheta2 target sequence, GGTCTCTGACTATCATGGAG)
(Gagnon et al., 2014; Montague et al., 2014). The pheta1vt2 allele
harbored a 38 bp deletion (frameshift), resulting in the deletion of a
MwoI restriction site, which was used to distinguish between WT and
pheta1vt2 alleles. Genomic DNA flanking the deletion was amplified by
PCR, followed by MwoI digestion for 2 h at 60°C (primer sequences 5′-
CCTCAAACAAACTAGCGGACGTGTCGAGTA-3′ and 5′-CGCGACA-
GAGCCTTTACCCATGATTCCATA-3′). After MwoI digestion, the cut
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WT bands were 230 bp and 300 bp in length, whereas the mutant band was
531 bp (uncut). The pheta2vt3 allele harbored an 11 bp deletion, resulting in
the deletion of an NlaIII restriction site, which was used to distinguish
between WT and pheta2vt3 alleles. Genomic DNA flanking the deletion
was amplified by PCR, followed by NlaIII digestion for 2 h at 37°C (primer
sequences 5′-GGACGGTCAGTTCTGTTTCTCT-3′ and 5′-CATGTAAA-
CATACCTTCGTATCGTC-3′). After NlaIII digestion, the cut WT bands
were 180 bp and 44 bp in length, whereas the mutant band was 213 bp
(uncut).
Tg(ubb:pheta1-GFP)vt4 and Tg(ubb:pheta1_R6C-GFP)vt5 transgenic
zebrafish lines were generated utilizing the Tol2-transgenesis system
(Kawakami, 2007). Coding sequence for EGFP was ligated in frame to
the 3′ end of the coding sequence of either the WT (Pheta1-GFP) or the
patient-specific (Pheta1_R6C-GFP) Pheta1 protein, and placed into the Tol2
vector, preceded by the zebrafish ubiquitin promoter from Mosimann et al.
(2011). The Tol2-ubb:pheta1-GFP and Tol2-ubb:pheta1_R6C-GFP
vectors were then injected with Tol2 transposase mRNA into WT
zebrafish larvae at the one-cell stage. Potential founders were crossed to
WT fish at 2-3 months of age, and offspring were screened for EGFP-
positive F1 founders.
RT-PCR analysis of pheta1 and pheta2 transcript
Total RNAwas isolated from pools of animals using an RNA Miniprep Kit
(Zymo). To determine whether CRISPR-induced deletions were
incorporated into transcribed mRNA, 50 ng of total RNA from 4 dpf WT,
pheta1−/− and pheta2−/− animals were used for first-strand cDNA synthesis
(SuperScript III, Thermo Fisher Scientific), followed by PCR amplification
(GoTaq G2 Green Master Mix, Promega). Purified PCR products were
sequenced by Sanger sequencing at the Virginia Tech Genome Sequencing
Center. Sequencing results confirmed that the CRISPR-induced 38 bp and
11 bp deletions were incorporated into the pheta1 and pheta2 transcripts,
respectively. To determine the expression of pheta1 and pheta2 during early
development, 300 ng of total RNA from 512-cell, 1 dpf, and 3 dpf WT
zebrafish was used for first-strand cDNA synthesis (LunaScript RT
SuperMix, NEB), followed by PCR amplification. Primers used were as
follows: pheta1, 5′-GGAAGAATCAAGGGAGAAAAACTGCG-3′ and
5′-TCCTCGAAGTAGAACAGCATGTTGCC-3′; pheta2, 5′-ACCCATT-
ACCTGTCCTGCACTTCAC-3′ and 5′-CTAGCCAAGATCAATGAGG-
TCCTCCTC-3′; rpl4, 5′-GTGCCCGACCGTTAATCTC-3′ and 5′-
ACACTGCTGGCATAACCACAT-3′.
Whole-mount in situ hybridization
In situ hybridization was performed using protocols described previously
(Pan et al., 2012; Prober et al., 2008). Sense and antisense probes were
transcribed from linearized plasmid DNA using a DIG RNA Labeling Kit
(Roche). pheta1 in situ probes were synthesized using pheta1-5′UTR
sequence (primer sequences 5′-TGGATCCGGAAGAATCAAGGGAG-3′
and 5′-TCTCGAGGAACAGCATGTTGCC-3′). The sox9a anti-sense
probes have been described previously (Flanagan-Steet et al., 2016).
Histochemistry and immunohistochemistry
Alcian Blue/Alizarin Red staining was performed using the ‘No acid’
protocol (Walker and Kimmel, 2007). Briefly, after fixation with 2%
paraformaldehyde and rinse with 50% ethanol, samples were stained
overnight in 0.04% Alcian Blue (Anatech)/0.01% Alizarin Red S
(Sigma-Aldrich)/10 mM MgCl2/80% ethanol. Stained samples were
rinsed in 80% ethanol/10 mM MgCl2 for several hours, and washed in
50% and 25% ethanol. After washing, samples were bleached in 3%
H2O2/0.5% KOH for 10 min with the cap open, followed by rinsing in
25% and 50% glycerol/0.1% KOH, and stored in 50% glyceron/0.1%
KOH. For Od treatment experiments, Alizarin Red S was not included in
the staining solution. Flat mount preparation was performed as described
by Javidan and Schilling (2004). Live staining of ceratohyal bone collar
was performed as described previously (Flanagan-Steet et al., 2016).
Fish at 7 dpf were placed in Eppendorf tubes and stained in 0.05%
Alizarin Red/10 mM HEPES pH 7.0 (Fisher Scientific)/E3 for 1 h in the
dark, rinsed in 10 mM/10 mM HEPES pH 7.0, and anesthetized in
0.013% tricaine (Fisher Scientific)/E3. Anesthetized animals were
mounted face down on an uncoated 50 mm glass-bottom Petri dish
(MatTek) in 1.7% low melting agarose (Fisher Scientific) in E3 buffer
for imaging.
Immunohistochemistry was performed as previously described (Randlett
et al., 2015). Primary antibodies were as follows: anti-acetylated α-tubulin
(T6793; Sigma-Aldrich; 1:1000), anti-γ-tubulin (T5326; Sigma-Aldrich;
1:100), anti-Znp-1 [ANZNP-1; Developmental Studies Hybridoma Bank
(DSHB); 1:25], anti-Zpr1 [zpr1; Zebrafish International Resource Center
(ZIRC); 1:100], anti-Zpr3 (zpr3; ZIRC; 1:100), anti-Collagen type II (II-
II6B3; DHSB; 1:100), anti-GFP (ab13970; Abcam; 1:1000). Alexa Fluor-
conjugated secondary antibodies (Life Technologies; 1:500), 4′,6-
diamidino-2-phenylindole (DAPI; D1306; Life Technologies; 1:1000)
and toto-3 (T3604, Life Technologies, 1:2000) were used after primary
antibody incubation.
To image Alcian Blue/Alizarin Red-stained samples, individual fish were
mounted on a glass slide in 50% glyceron/0.1% KOH and imaged using a
Nikon SMZ18 fluorescent stereomicroscope with an image capture system.
To image ceratohyal chondrocytes, flat-mount specimens were imaged
under bright-field illumination using a Zeiss Axio Imager 1 upright
compound microscope with a 20× objective. For fluorescent imaging,
animals were mounted on an uncoated 50 mm glass-bottom Petri dish
(MatTek) in 1.7% lowmelting agarose (Fisher Scientific) and imaged with a
Nikon SMZ18 fluorescent stereomicroscope or a Nikon A1 laser scanning
confocal system with a CF175 Apochromat LWD 25× water-immersion
objective. The same imaging settings were used for all samples in each
experiment.
Injection of endocytic tracers and analysis
Lysine-fixable 10 kDa dextran (Alexa Fluor 488 conjugated) or 500 kDa
dextran [fluorescein isothiocyanate (FITC) conjugated] (Thermo Fisher
Scientific) were prepared in PBS at 2 µg/µl final concentration. In addition,
recombinant Cy3-conjugated His-tagged RAP (39 kDa), prepared in PBS at
5 µg/µl final concentration, was kindly provided by Dr Martin Lowe
(University of Manchester, Manchester, UK). Zebrafish embryos were
anesthetized in tricaine (0.013% w/v; Fisher Scientific) diluted in
embryo water at 72 hpf. Approximately 0.5-1 nl of dextran or RAP was
injected into the common cardinal vein using a glass micropipette and a
pneumatic pressure injector (PLI90; Harvard Apparatus) and
micromanipulator. Uptake in the renal tubular cells of the proximal
pronephros was analyzed at 1-2.5 hpi, using a Nikon SMZ18 fluorescent
stereomicroscope with an image capture system. High dextran uptake
was defined as >20 fluorescent puncta observed along the proximal
pronephros. Low dextran uptake was defined as one to 20 fluorescent
puncta observed along the proximal pronephros, and no uptake indicated
that no fluorescent puncta were seen. Animals injected with 500 kDa
dextran were analyzed at 24 hpi.
MO inhibition of ocrl gene expression
The ocrl translation-blocking MO (a gift from DrMartin Lowe, University of
Manchester) has previously been described (sequence AATCCCAA-
ATGAAGGTTCCATCATG) (Coon et al., 2012). MO was injected into
embryos at the one-cell stage at 1-5 ng/µl.
Cilia and craniofacial quantification and analysis
Cilia in the anterior ( just anterior to the yolk extension) and posterior (near
the cloacae) portion of the pronephros in the zebrafish larvae were imaged
and analyzed. The number of cilia within a 100×100 µm2 area were
quantified, and the length of five randomly selected cilia was measured
within the area. Craniofacial morphological measurements were performed
with Fiji (Schindelin et al., 2012). Type II collagen was quantified by mean
fluorescence intensity within a 2500 µm2 area in the ceratohyal cartilage and
a 1000 µm2 area in Meckel’s cartilage.
BMV109 delivery and in-gel analyses
The BMV109 fluorescent ABP was injected into 3 dpf larvae (1 nl at
10 µM) pericardially via microinjection. This equates to a final global
concentration of 10 nM. Probe was circulated overnight at 28.8°C and
harvested at 15 hpi. Twenty-five larvae per condition were collected and
14


















lysed in citrate buffer (50 mM citrate buffer pH 5.5, 5 mM DTT, 0.5%
CHAPS, 0.75% Triton X-100) by brief sonication. Samples were
centrifuged for 15 min at 15,000 g and the supernatant collected. Protein
concentration was determined via a micro BCA assay (23235; Thermo
Fisher Scientific) and samples run on 4-20% precast gradient gels
containing the ‘stain free’ tri-halo compound (Bio-Rad). UV light-
activated tri-halo covalently binds tryptophan residues. Equivalent protein
loads were evaluated on a Bio-Rad Chemidoc MP Imaging System using
this stain-free method. BMV109 Cy5 fluorescence was subsequently
analyzed in gel. Total protein load per lane and individual ABP-reactive
bands were quantitated using Chemidoc MP software. Individual ABP-
reactive bands were normalized to total protein load and the fold difference
calculated between WT and MLII samples.
Pharmacological inhibition
Cathepsin K activity was inhibited from 3 dpf to 4 dpf in live embryos by
introducing 25 nM and 50 nM Od [solubilized in dimethyl sulfoxide
(DMSO)] directly into their growth medium. In all cases, WT control larvae
were treated with an equivalent amount of DMSO (0.1%).
Cell culture
HeLa cells (ATCC CCL-2) were grown in DMEM supplemented with 5%
FBS (Thermo Fisher Scientific) and 1% penicillin-streptomycin (Life
Technologies). Cells were transfected using Effectene (Qiagen) according to
instructions provided by the manufacturer. The PHETA1 cDNA was
synthesized by Genewiz and cloned into the pEGFP-C3 vector (Promega).
The R6Cmutation was introduced into the construct using a Q5 site-directed
mutagenesis kit (NEB). The pcDNA3-HA-human OCRL plasmid was
Addgene plasmid #22207 (http://n2t.net/addgene:22207; RRID:
Addgene_22207), deposited by Pietro De Camilli.
Protein-protein interaction
Lysates were prepared from transfected HeLa cells by incubating the cell
pellet in RIPA buffer (50 mM Tris-Cl pH 7.5, 150 nM NaCl, 1% NP40,
1 mM EDTA). The lysate was clarified by centrifugation at 10,000 g
for 5 min at 40°C. Then, 1× Halt protease inhibitor cocktail (Pierce)
was added to the lysate, with 800 µg total protein used per
immunoprecipitation. Immunoprecipitation was performed using GFP-
Trap beads (Chromotek) in binding buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 0.2 mM EDTA, 0.05% NP40). The lysate was incubated with
beads for 75 min at 40°C. Subsequently, the beads were washed four
times using binding buffer. The bound proteins were eluted by boiling in
Laemmli buffer, run on a gel and analyzed by western blotting. A
monoclonal GFP antibody (JL-8; Clontech) and a monoclonal
hemagglutinin (HA) antibody (sc-7392; Santa Cruz Biotechnology)
were used in the western blot analyses. The HRP signal was acquired on a
Chemidoc MP (Bio-Rad) imaging system.
RNA-seq analysis of transcript abundance in zebrafish
Total RNA from WT, pheta1−/− and dKO larvae (5 dpf, head only) was
isolated using an RNAMiniprep Kit (Zymo). Three biological replicates for
each group were analyzed, each containing RNA from a pool of ten animals.
All samples had an RNA integrity number ≥8.0 and were converted into a
strand-specific library using Illumina’s TruSeq Stranded mRNAHT Sample
Prep Kit (Illumina, RS-122-2103) for subsequent cluster generation and
sequencing on Illumina’s NextSeq. The library was enriched by 13 cycles of
PCR, validated using Agilent TapeStation and quantitated by qPCR.
Individually indexed cDNA libraries were pooled and sequenced on
NextSeq 75 SR to obtain a minimum of 30 million reads/sample. Following
sequencing, data were trimmed for both adaptor and quality using a
combination of ea-utils and Btrim (Aronesty, 2013; Kong, 2011).
Sequencing reads were then aligned to the genome (Ensembl
Danio_rerio.GRCz11.92 with and without unplaced contigs) using
Tophat2/HiSat2 (Kim et al., 2015) and counted via HTSeq (Anders et al.,
2015). Read counts for genes annotated on the unplaced contigs were added
to the chromosome-only count summary. QC summary statistics were
examined to identify any problematic samples [e.g. total read counts, quality
and base composition profiles (+/− trimming)], raw fastq-formatted data
files, aligned files (bam and text file containing sample alignment statistics)
and count files (HTSeq text files). The data discussed in this
publication have been deposited in NCBI’s Gene Expression Omnibus
(GEO) (Edgar et al., 2002) and are accessible through GEO series accession
number GSE142673 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE142673). The expression of pheta1, pheta2 and condrogenesis genes
(col2a1a, acana, dcn, sox9a) was compared using two-way repeated-measures
ANOVAwith Holm-Sidak correction.
OKR in zebrafish
VisioTracker 302060 (New Behavior TSE) was used for OKR assay. Eye
movements of individual fish were recorded at five frames/s by an overhead
CCD camera. Zebrafish larvae were placed in the center of an uncoated
50 mm glass-bottom Petri dish (MatTek) and immobilized in 1.5-2% low
melting agarose (Fisher Scientific) in E3 buffer. Agarose around the eyewas
removed with forceps to allow free eye movement. The dish was then filled
with water. To test slow-phase performance under short periodicity, the
direction of black and white grating switched every 3 s with grating velocity
at 7.5°/s. Each experimental run (trial) was 108 s long and included twelve
9-s phases at varying contrast levels (0.99, 1.0, 0.5, 0.2, 0.1, 0.05, 0.02, 0.05,
0.1, 0.2, 0.5, 1.0). Five to six trials were tested for each animal. Contrast
sensitivity and eye correlation were calculated using custom MATLAB
scripts (available upon request).
Image processing and statistical analyses
Images were quantified with Fiji (Schindelin et al., 2012), and figures were
made in Photoshop (Adobe Systems). All statistical analyses were
performed in GraphPad Prism (Version 8). Chi-square tests were used to
analyze categorical data from endocytosis assays. For normally distributed
data, parametric tests (Student’s t-test or ANOVA) were used. For ANOVA
tests, the Holm-Sidak post-test was performed to correct for multiple
comparisons. For non-normally distributed data, non-parametric tests
(Mann–Whitney U, Kruskal–Wallis) were used. Dunn’s correction was
used to correct for multiple comparisons after Kruskal–Wallis tests. All
values are expressed as mean±s.e.m., unless otherwise noted. The test was
considered significant when P<0.05.
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